We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Nanopore Method Detects Single Influenza Virus at Single Particle Level

By LabMedica International staff writers
Posted on 03 Dec 2018
A team of Japanese researchers has introduced a novel sensor concept capable of discriminating various types of influenza virus in a label-free fashion by their distinct particle properties.

Rapid diagnosis of influenza infection before onset of symptoms would improve health care by reducing risk for serious complications as well as by preventing infectious disease outbreaks. More...
Sensor sensitivity and selectivity are critical to accomplishing this goal, as the number of virus particles is quite small at the early stage of infection.

To overcome the low particle number problem, investigators at Osaka University (Japan) developed a nanopore device with electroosmotic flow (liquid motion induced by an electric current across the nanopore) properties that ensured that the pore channel would block the passage of non-virus particles. The nanopores were designed to have low thickness-to-diameter aspect-ratio structure so as to render additional sensitivity to the particle shape and surface charges. This provided resistive pulses holding a complex set of information concerning not only the nanoparticle volume but multiple physical properties of the intact viral particles.

To evaluate the information set, the investigators employed machine-learning-driven pattern-analysis of the electrical signatures. This allowed for rapid detection and simultaneous subtype differentiation of virus particles with an ultimate sensitivity of single-particle discriminations. Results demonstrated the ability to identify allotypes with 68% accuracy at the single-virus level.

"We used machine-learning analysis of the electrical signatures of the virions," said contributing author Dr. Makusu Tsutsui, associate professor of scientific and industrial research at Osaka University. "Using this artificial intelligence approach to signal analysis, our method can recognize a slight current waveform difference, which cannot be discerned by human eyes. This enables high-precision identification of viruses."

"Our testing revealed that this new sensor may be suitable for use in a viral test kit that is both quick and simple," said first author Akihide Arima, a researcher in the chemistry department at Osaka University. "Importantly, use of this sensor does not require specialized human expertise, so it can readily be applied as a point-of-care screening approach by a wide variety of healthcare personnel."

The nanopore technique for detecting influenza virus was described in the November 2, 2018, online edition of the journal Scientific Reports.

Related Links:
Osaka University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.